Valneva SE

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

04 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

29 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

15 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA: Declaration of shares and voting rights - January 31, 2024

07 Feb 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva Announces Sale of Priority Review Voucher for $103 Million

05 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

10 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: December 31, 2023

05 Jan 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

04 Jan 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva Provides Updated 2023 Financial Guidance

29 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

20 Dec 2023 11:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - November 30, 2023

06 Dec 2023 02:30:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

04 Dec 2023 16:20:00 By Nasdaq GlobeNewswire

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

04 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

27 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 Nov 2023 01:30:00 By Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 Nov 2023 02:30:00 By Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 Oct 2023 12:15:00 By Nasdaq GlobeNewswire